Renaissance Technologies LLC Acquires Shares of 522,900 Treace Medical Concepts, Inc. $TMCI

Posted by on Aug 17th, 2026

Renaissance Technologies LLC bought a new position in Treace Medical Concepts, Inc. (NASDAQ:TMCI – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 522,900 shares of the company’s stock, valued at approximately $701,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Osaic Holdings Inc. lifted its position in shares of Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after purchasing an additional 3,674 shares during the last quarter. Captrust Financial Advisors purchased a new position in Treace Medical Concepts in the 2nd quarter worth about $62,000. Graham Capital Management L.P. purchased a new position in Treace Medical Concepts in the 4th quarter worth about $27,000. Mercer Global Advisors Inc. ADV bought a new stake in Treace Medical Concepts during the 3rd quarter valued at about $87,000. Finally, HighTower Advisors LLC bought a new stake in Treace Medical Concepts during the 4th quarter valued at about $33,000. 84.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Treace Medical Concepts news, CEO John T. Treace bought 61,202 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were acquired at an average price of $3.02 per share, with a total value of $184,830.04. Following the transaction, the chief executive officer owned 7,273,833 shares of the company’s stock, valued at approximately $21,966,975.66. This trade represents a 0.85% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have bought 217,837 shares of company stock worth $729,134. Company insiders own 23.42% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Truist Financial boosted their price objective on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Wall Street Zen raised shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $5.17.

Check Out Our Latest Research Report on TMCI

Treace Medical Concepts Price Performance

TMCI opened at $4.79 on Monday. Treace Medical Concepts, Inc. has a 12-month low of $1.17 and a 12-month high of $7.78. The company has a current ratio of 2.90, a quick ratio of 1.95 and a debt-to-equity ratio of 0.83. The business’s fifty day simple moving average is $4.30 and its 200-day simple moving average is $2.82. The company has a market capitalization of $311.54 million, a price-to-earnings ratio of -5.15 and a beta of 1.37.

Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.06. The firm had revenue of $45.38 million for the quarter, compared to analyst estimates of $44.02 million. Treace Medical Concepts had a negative return on equity of 71.37% and a negative net margin of 28.99%. On average, equities research analysts anticipate that Treace Medical Concepts, Inc. will post -0.83 earnings per share for the current fiscal year.

About Treace Medical Concepts

(Free Report)

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.

Featured Stories

Want to see what other hedge funds are holding TMCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Treace Medical Concepts, Inc. (NASDAQ:TMCI – Free Report).

Institutional Ownership by Quarter for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.